These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 37770850)

  • 1. Genotypic and phenotypic comparison of drug resistance profiles of clinical multidrug-resistant Mycobacterium tuberculosis isolates using whole genome sequencing in Latvia.
    Vīksna A; Sadovska D; Berge I; Bogdanova I; Vaivode A; Freimane L; Norvaiša I; Ozere I; Ranka R
    BMC Infect Dis; 2023 Sep; 23(1):638. PubMed ID: 37770850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of whole genome sequencing versus phenotypic (MGIT) and commercial molecular tests for detection of drug-resistant Mycobacterium tuberculosis isolated from patients in Brazil and Mozambique.
    Feliciano CS; Namburete EI; Rodrigues Plaça J; Peronni K; Dippenaar A; Warren RM; Silva WA; Bollela VR
    Tuberculosis (Edinb); 2018 May; 110():59-67. PubMed ID: 29779775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of drug resistance by Sanger sequencing of Mycobacterium tuberculosis complex strains isolated from multidrug resistant tuberculosis suspect patients in Ethiopia.
    Mesfin EA; Merker M; Beyene D; Tesfaye A; Shuaib YA; Addise D; Tessema B; Niemann S
    PLoS One; 2022; 17(8):e0271508. PubMed ID: 35930613
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study.
    Penn-Nicholson A; Georghiou SB; Ciobanu N; Kazi M; Bhalla M; David A; Conradie F; Ruhwald M; Crudu V; Rodrigues C; Myneedu VP; Scott L; Denkinger CM; Schumacher SG;
    Lancet Infect Dis; 2022 Feb; 22(2):242-249. PubMed ID: 34627496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin.
    Pillay S; Steingart KR; Davies GR; Chaplin M; De Vos M; Schumacher SG; Warren R; Theron G
    Cochrane Database Syst Rev; 2022 May; 5(5):CD014841. PubMed ID: 35583175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-genome sequencing in drug susceptibility testing of Mycobacterium tuberculosis in routine practice in Lyon, France.
    Genestet C; Hodille E; Berland JL; Ginevra C; Bryant JE; Ader F; Lina G; Dumitrescu O;
    Int J Antimicrob Agents; 2020 Apr; 55(4):105912. PubMed ID: 31991222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Whole-Genome Sequencing to Predict
    Wu X; Tan G; Sha W; Liu H; Yang J; Guo Y; Shen X; Wu Z; Shen H; Yu F
    Microbiol Spectr; 2022 Apr; 10(2):e0251621. PubMed ID: 35311541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and Assessment of a Novel Whole-Gene-Based Targeted Next-Generation Sequencing Assay for Detecting the Susceptibility of Mycobacterium tuberculosis to 14 Drugs.
    Wu SH; Xiao YX; Hsiao HC; Jou R
    Microbiol Spectr; 2022 Dec; 10(6):e0260522. PubMed ID: 36255328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determining Genotypic Drug Resistance by Ion Semiconductor Sequencing With the Ion AmpliSeq™ TB Panel in Multidrug-Resistant Mycobacterium tuberculosis Isolates.
    Park J; Shin SY; Kim K; Park K; Shin S; Ihm C
    Ann Lab Med; 2018 Jul; 38(4):316-323. PubMed ID: 29611381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of whole-genome sequencing and phenotypic drug susceptibility testing for Mycobacterium tuberculosis causing MDR-TB and XDR-TB in Thailand.
    Faksri K; Kaewprasert O; Ong RT; Suriyaphol P; Prammananan T; Teo YY; Srilohasin P; Chaiprasert A
    Int J Antimicrob Agents; 2019 Aug; 54(2):109-116. PubMed ID: 30981926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-resistance to isoniazid and second-line anti-tuberculosis drugs in isoniazid-resistant tuberculosis at a tertiary care hospital in Thailand.
    Prommi A; Wongjarit K; Petsong S; Somsukpiroh U; Faksri K; Kawkitinarong K; Payungporn S; Rotcheewaphan S
    Microbiol Spectr; 2024 Mar; 12(3):e0346223. PubMed ID: 38323824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotypic drug resistance using whole-genome sequencing of Mycobacterium tuberculosis clinical isolates from North-western Tanzania.
    Kidenya BR; Mshana SE; Fitzgerald DW; Ocheretina O
    Tuberculosis (Edinb); 2018 Mar; 109():97-101. PubMed ID: 29559127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-genome sequencing of presumptive MDR-TB isolates from a tertiary healthcare setting in Mumbai.
    Zade A; Shah S; Hirani N; Kondabagil K; Joshi A; Chatterjee A
    J Glob Antimicrob Resist; 2022 Dec; 31():256-262. PubMed ID: 36272707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-genome sequence analysis and comparisons between drug-resistance mutations and minimum inhibitory concentrations of Mycobacterium tuberculosis isolates causing M/XDR-TB.
    Nonghanphithak D; Kaewprasert O; Chaiyachat P; Reechaipichitkul W; Chaiprasert A; Faksri K
    PLoS One; 2020; 15(12):e0244829. PubMed ID: 33382836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Whole-genome sequencing reveals genotypic resistance in phenotypically susceptible
    Hasan Z; Razzak SA; Kanji A; Shakoor S; Hasan R
    Int J Mycobacteriol; 2023; 12(2):179-183. PubMed ID: 37338481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Five User-Friendly Whole Genome Sequencing Software for
    Kim N; Seok KH; Shin S; Kim B; Park H; Roh EY; Yoon JH; Shin S
    J Korean Med Sci; 2022 Nov; 37(46):e328. PubMed ID: 36631026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the clinical impact of routine whole genome sequencing in tuberculosis treatment decisions and the issue of isoniazid mono-resistance.
    Park M; Lalvani A; Satta G; Kon OM
    BMC Infect Dis; 2022 Apr; 22(1):349. PubMed ID: 35392842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of WHO catalog of mutations and five WGS analysis tools for drug resistance prediction of
    He G; Zheng Q; Shi J; Wu L; Huang B; Yang Y
    Microbiol Spectr; 2024 Aug; 12(8):e0334123. PubMed ID: 38904370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of mutations associated with resistance to second-line tuberculosis drug among multidrug-resistant tuberculosis patients from high prevalence tuberculosis city in Morocco.
    Oudghiri A; Karimi H; Chetioui F; Zakham F; Bourkadi JE; Elmessaoudi MD; Laglaoui A; Chaoui I; El Mzibri M
    BMC Infect Dis; 2018 Feb; 18(1):98. PubMed ID: 29486710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.
    Heyckendorf J; Andres S; Köser CU; Olaru ID; Schön T; Sturegård E; Beckert P; Schleusener V; Kohl TA; Hillemann D; Moradigaravand D; Parkhill J; Peacock SJ; Niemann S; Lange C; Merker M
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.